^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    DC-AdGMCAIX

    i
    Other names: DC-AdGMCAIX, DC AdGM CAIX, Ad-GMCAIX transduced dendritic cells, AdGMCA9, DCs expressing CMCA9 gene therapy, AdGMCAIX-transduced dendritic cells
    Associations

    News

    Trials
    Company:
    Gilead
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    over3years
    Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer (clinicaltrials.gov)
    P1, N=12, Completed, Jonsson Comprehensive Cancer Center | Active, not recruiting --> Completed | Trial completion date: Jan 2022 --> May 2021
    Clinical • Trial completion • Trial completion date
    |
    CA9 (Carbonic anhydrase 9)
    |
    DC-AdGMCAIX
    4years
    A Phase I, Open-label, Dose-escalation, and Cohort Expansion Study to Evaluate the Safety and Immune Response to Autologous Dendritic Cells Transduced With AdGMCA9 (DC-AdGMCAIX) in Patients With Metastatic Renal Cell Carcinoma. (PubMed, J Immunother)
    These early data show that autologous immature DC-AdGMCAIX can be safely given to metastatic RCC patients without any serious adverse events with CAIX-specific immune response elicited by the treatment. These preliminary data support further study of Ad-GMCAIX, particularly with combination therapies that may enhance clinical activity.
    Clinical • Journal
    |
    CA9 (Carbonic anhydrase 9)
    |
    CA9 expression
    |
    DC-AdGMCAIX
    over4years
    Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Jan 2020 --> Jan 2022 | Trial primary completion date: Dec 2019 --> Dec 2021
    Clinical • Trial completion date • Trial primary completion date
    |
    CA9 (Carbonic anhydrase 9)
    |
    DC-AdGMCAIX